CEL SCI Ownership
| CVM Stock | USD 0.67 0.02 2.91% |
Shares in Circulation | First Issued 2009-06-30 | Previous Quarter 52 M | Current Value 54 M | Avarage Shares Outstanding 17.7 M | Quarterly Volatility 18.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
CEL |
CEL Stock Ownership Analysis
The company recorded a loss per share of 0.52. CEL SCI Corp last dividend was issued on the 28th of August 1996. The entity had 1:25 split on the 15th of June 2017. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Cel-Sci Corp operates under Biotechnology classification in the United States and is traded on AMEX Exchange. For more info on CEL SCI Corp please contact Geert Kersten at 703 506 9460 or go to https://cel-sci.com.CEL SCI Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CEL SCI insiders, such as employees or executives, is commonly permitted as long as it does not rely on CEL SCI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CEL SCI insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CEL SCI Outstanding Bonds
CEL SCI issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. CEL SCI Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CEL bonds can be classified according to their maturity, which is the date when CEL SCI Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| CE 605 15 MAR 25 Corp BondUS15089QAL86 | View | |
| CE 6165 15 JUL 27 Corp BondUS15089QAM69 | View | |
| CE 14 05 AUG 26 Corp BondUS15089QAK04 | View | |
| CE 6379 15 JUL 32 Corp BondUS15089QAP90 | View | |
| CE 633 15 JUL 29 Corp BondUS15089QAN43 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.